Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug?
Gaurav Goel Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Abstract: Colorectal cancer (CRC) is a major public health problem in the United States with an estimated 50,260 deaths in 2017. Over the past two decades, several agents have been approved...
সংরক্ষণ করুন:
| প্রধান লেখক: | |
|---|---|
| বিন্যাস: | Artigo |
| ভাষা: | Inglês |
| প্রকাশিত: |
Dove Medical Press
2018-03-01
|
| মালা: | Cancer Management and Research |
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://www.dovepress.com/evolution-of-regorafenib-from-bench-to-bedside-in-colorectal-cancer-is-peer-reviewed-article-CMAR |
| ট্যাগগুলো: |
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|